|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1976-1-2
|
|
pubmed:abstractText |
77 unselected adult patients with acute myeloblastic leukaemia (AML), including practically all AML patients from an area with 1.9 million inhabitants, were randomized for either (1) 5 days pretreatment with 1-asparaginase and prednisolone followed by a combination of rubidomycin and cytosine arabinoside (ARAP), or (2) treatment with a combination of rubidomycin, cytosine arabinoside and prednisolone without 1-asparaginase pretreatment (RAP). Complete remission was induced with ARAP in 12 patients (31%) and with RAP in 13 patients (34%). Thus pretreatment with 1-asparaginase did not improve the therapeutic response. The overall remission frequency was significantly higher below the age of 60; 50% compared to 13% above this age. Side-effects such as liver dysfunction, nausea and vomiting were more common in patients pretreated with 1-asparaginase. Sterilization of the gut did not improve the remission frequency with either regime.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0036-553X
|
|
pubmed:author |
pubmed-author:BrenningGG,
pubmed-author:EngstedtLL,
pubmed-author:FranzénSS,
pubmed-author:GahrtonGG,
pubmed-author:GullbringBB,
pubmed-author:HöglundSS,
pubmed-author:HolmGG,
pubmed-author:JamesonSS,
pubmed-author:KillanderAA,
pubmed-author:KillanderDD,
pubmed-author:LocknerDD,
pubmed-author:MellstedtHH,
pubmed-author:PalmbladJJ,
pubmed-author:ReizensteinPP,
pubmed-author:SkårbergK OKO,
pubmed-author:SwedbergBB,
pubmed-author:UdénA MAM,
pubmed-author:WadmanBB,
pubmed-author:WideLL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
72-80
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1058527-Adolescent,
pubmed-meshheading:1058527-Adult,
pubmed-meshheading:1058527-Age Factors,
pubmed-meshheading:1058527-Aged,
pubmed-meshheading:1058527-Asparaginase,
pubmed-meshheading:1058527-Cytarabine,
pubmed-meshheading:1058527-Daunorubicin,
pubmed-meshheading:1058527-Drug Administration Schedule,
pubmed-meshheading:1058527-Drug Therapy, Combination,
pubmed-meshheading:1058527-Female,
pubmed-meshheading:1058527-Humans,
pubmed-meshheading:1058527-Leukemia, Myeloid, Acute,
pubmed-meshheading:1058527-Leukocyte Count,
pubmed-meshheading:1058527-Male,
pubmed-meshheading:1058527-Middle Aged,
pubmed-meshheading:1058527-Nausea,
pubmed-meshheading:1058527-Prednisolone,
pubmed-meshheading:1058527-Remission, Spontaneous,
pubmed-meshheading:1058527-Vomiting
|
|
pubmed:year |
1975
|
|
pubmed:articleTitle |
L-asparaginase and prednisolone pretreatment followed by rubidomycin and cytosine arabinoside for induction of remission in adult patients with acute myeloblastic leukaemia.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
